vs
Side-by-side financial comparison of RELIANCE, INC. (RS) and Zoetis (ZTS). Click either name above to swap in a different company.
RELIANCE, INC. is the larger business by last-quarter revenue ($4.0B vs $2.3B, roughly 1.8× Zoetis). Zoetis runs the higher net margin — 26.6% vs 6.6%, a 20.0% gap on every dollar of revenue. On growth, RELIANCE, INC. posted the faster year-over-year revenue change (15.1% vs 2.9%). Over the past eight quarters, RELIANCE, INC.'s revenue compounded faster (5.1% CAGR vs -2.1%).
Reliance, Inc. (Reliance), headquartered in Scottsdale, Arizona, is the largest metals service center operator in North America. The company provides metals processing services and distributes a line of approximately 100,000 metal products, including aluminum, brass, alloy, copper, carbon steel, stainless steel, titanium, and specialty metal products to 125,000 customers such as fabricators and manufacturers.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
RS vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.0B | $2.3B |
| Net Profit | $265.6M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 9.1% | — |
| Net Margin | 6.6% | 26.6% |
| Revenue YoY | 15.1% | 2.9% |
| Net Profit YoY | 32.5% | -0.2% |
| EPS (diluted) | $5.10 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $4.0B | $2.3B | ||
| Q4 25 | $3.5B | $2.4B | ||
| Q3 25 | $3.7B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $3.5B | $2.2B | ||
| Q4 24 | $3.1B | $2.3B | ||
| Q3 24 | $3.4B | $2.4B | ||
| Q2 24 | $3.6B | $2.4B |
| Q1 26 | $265.6M | $601.0M | ||
| Q4 25 | $116.9M | $603.0M | ||
| Q3 25 | $189.5M | $721.0M | ||
| Q2 25 | $234.2M | $718.0M | ||
| Q1 25 | $200.5M | $631.0M | ||
| Q4 24 | $106.0M | $581.0M | ||
| Q3 24 | $199.2M | $682.0M | ||
| Q2 24 | $268.3M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 9.1% | — | ||
| Q4 25 | 4.8% | 31.9% | ||
| Q3 25 | 7.1% | 37.0% | ||
| Q2 25 | 8.5% | 36.7% | ||
| Q1 25 | 7.9% | 36.5% | ||
| Q4 24 | 4.5% | 31.6% | ||
| Q3 24 | 8.0% | 36.6% | ||
| Q2 24 | 9.7% | 33.0% |
| Q1 26 | 6.6% | 26.6% | ||
| Q4 25 | 3.3% | 25.3% | ||
| Q3 25 | 5.2% | 30.0% | ||
| Q2 25 | 6.4% | 29.2% | ||
| Q1 25 | 5.8% | 28.4% | ||
| Q4 24 | 3.4% | 25.1% | ||
| Q3 24 | 5.8% | 28.6% | ||
| Q2 24 | 7.4% | 26.4% |
| Q1 26 | $5.10 | $1.42 | ||
| Q4 25 | $2.23 | $1.37 | ||
| Q3 25 | $3.59 | $1.63 | ||
| Q2 25 | $4.42 | $1.61 | ||
| Q1 25 | $3.74 | $1.41 | ||
| Q4 24 | $2.05 | $1.29 | ||
| Q3 24 | $3.61 | $1.50 | ||
| Q2 24 | $4.67 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $249.7M | — |
| Total DebtLower is stronger | $1.7B | — |
| Stockholders' EquityBook value | $7.1B | — |
| Total Assets | $10.8B | — |
| Debt / EquityLower = less leverage | 0.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $249.7M | — | ||
| Q4 25 | $216.6M | — | ||
| Q3 25 | $261.2M | $2.1B | ||
| Q2 25 | $239.5M | $1.4B | ||
| Q1 25 | $277.8M | $1.7B | ||
| Q4 24 | $318.1M | $2.0B | ||
| Q3 24 | $314.6M | $1.7B | ||
| Q2 24 | $350.8M | $1.6B |
| Q1 26 | $1.7B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.2B | $3.3B | ||
| Q3 25 | $7.3B | $5.4B | ||
| Q2 25 | $7.2B | $5.0B | ||
| Q1 25 | $7.1B | $4.7B | ||
| Q4 24 | $7.2B | $4.8B | ||
| Q3 24 | $7.4B | $5.2B | ||
| Q2 24 | $7.6B | $5.0B |
| Q1 26 | $10.8B | — | ||
| Q4 25 | $10.4B | $15.5B | ||
| Q3 25 | $10.5B | $15.2B | ||
| Q2 25 | $10.5B | $14.5B | ||
| Q1 25 | $10.4B | $14.1B | ||
| Q4 24 | $10.0B | $14.2B | ||
| Q3 24 | $10.3B | $14.4B | ||
| Q2 24 | $10.4B | $14.2B |
| Q1 26 | 0.24× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $151.4M | — |
| Free Cash FlowOCF − Capex | $87.2M | — |
| FCF MarginFCF / Revenue | 2.2% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | 0.57× | — |
| TTM Free Cash FlowTrailing 4 quarters | $612.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $151.4M | — | ||
| Q4 25 | $276.1M | $893.0M | ||
| Q3 25 | $261.8M | $938.0M | ||
| Q2 25 | $229.0M | $486.0M | ||
| Q1 25 | $64.5M | $587.0M | ||
| Q4 24 | $473.3M | $905.0M | ||
| Q3 24 | $463.9M | $951.0M | ||
| Q2 24 | $366.3M | $502.0M |
| Q1 26 | $87.2M | — | ||
| Q4 25 | $202.9M | $732.0M | ||
| Q3 25 | $180.6M | $805.0M | ||
| Q2 25 | $141.4M | $308.0M | ||
| Q1 25 | $-22.4M | $438.0M | ||
| Q4 24 | $362.4M | $689.0M | ||
| Q3 24 | $351.1M | $784.0M | ||
| Q2 24 | $268.1M | $370.0M |
| Q1 26 | 2.2% | — | ||
| Q4 25 | 5.8% | 30.7% | ||
| Q3 25 | 4.9% | 33.5% | ||
| Q2 25 | 3.9% | 12.5% | ||
| Q1 25 | -0.6% | 19.7% | ||
| Q4 24 | 11.6% | 29.7% | ||
| Q3 24 | 10.3% | 32.8% | ||
| Q2 24 | 7.4% | 15.7% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | 2.1% | 6.7% | ||
| Q3 25 | 2.2% | 5.5% | ||
| Q2 25 | 2.4% | 7.2% | ||
| Q1 25 | 2.5% | 6.7% | ||
| Q4 24 | 3.5% | 9.3% | ||
| Q3 24 | 3.3% | 7.0% | ||
| Q2 24 | 2.7% | 5.6% |
| Q1 26 | 0.57× | — | ||
| Q4 25 | 2.36× | 1.48× | ||
| Q3 25 | 1.38× | 1.30× | ||
| Q2 25 | 0.98× | 0.68× | ||
| Q1 25 | 0.32× | 0.93× | ||
| Q4 24 | 4.47× | 1.56× | ||
| Q3 24 | 2.33× | 1.39× | ||
| Q2 24 | 1.37× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RS
Segment breakdown not available.
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
